Icosapent ethyl ($ VASCEPA^{®} $) as treatment for post-acute sequelae of SARS CoV-2 (PASC) vaccine induced injury and infection
Objectives As the COVID-19 pandemic continues, a prolonged post-infectious syndrome or “long COVID” has been reported. This is a multi-organ post viral syndrome that persists well after infection. Currently, there is no available treatment. Emerging evidence credits this “long COVID” syndrome to ongoing inflammatory response following resolution of symptoms during infection. An omega-three fatty acid derivative used in the treatment of hypertriglyceridemia, Icosapent Ethyl (IPE, $ VASCEPA^{®} $/$ Epadel^{®} $), was previously shown to reduce cardiovascular risk, likely via immunomodulatory effects. This study aims to evaluate the effectiveness of Icosapent Ethyl. Methods Following previous publications in treatment of severe acute COVID-19, we analyze two case studies of adults treated with Icosapent Ethyl. Results After experiencing the symptoms of Long Covid, both individuals analyzed across two case studies experiences a resolution of symptoms after treatment with Icosapent Ethyl. Conclusion After review and analysis we conclude that Icosapent Ethyl may have been a determining factor in Long COVID symptom resolution and should be studied further..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Journal of complementary and integrative medicine - 20(2023), 3 vom: 07. Juni, Seite 662-664 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cruess, Sean M. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2023 Walter de Gruyter GmbH, Berlin/Boston |
|---|
| doi: |
10.1515/jcim-2023-0129 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY009169075 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY009169075 | ||
| 003 | DE-627 | ||
| 005 | 20231205155314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230830s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/jcim-2023-0129 |2 doi | |
| 035 | |a (DE-627)GRUY009169075 | ||
| 035 | |a (DE-B1597)jcim-2023-0129-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 050 |q VZ |
| 084 | |a 44.98 |2 bkl | ||
| 100 | 1 | |a Cruess, Sean M. |e verfasserin |0 (orcid)0000-0003-0981-1873 |4 aut | |
| 245 | 1 | 0 | |a Icosapent ethyl ($ VASCEPA^{®} $) as treatment for post-acute sequelae of SARS CoV-2 (PASC) vaccine induced injury and infection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Walter de Gruyter GmbH, Berlin/Boston | ||
| 520 | |a Objectives As the COVID-19 pandemic continues, a prolonged post-infectious syndrome or “long COVID” has been reported. This is a multi-organ post viral syndrome that persists well after infection. Currently, there is no available treatment. Emerging evidence credits this “long COVID” syndrome to ongoing inflammatory response following resolution of symptoms during infection. An omega-three fatty acid derivative used in the treatment of hypertriglyceridemia, Icosapent Ethyl (IPE, $ VASCEPA^{®} $/$ Epadel^{®} $), was previously shown to reduce cardiovascular risk, likely via immunomodulatory effects. This study aims to evaluate the effectiveness of Icosapent Ethyl. Methods Following previous publications in treatment of severe acute COVID-19, we analyze two case studies of adults treated with Icosapent Ethyl. Results After experiencing the symptoms of Long Covid, both individuals analyzed across two case studies experiences a resolution of symptoms after treatment with Icosapent Ethyl. Conclusion After review and analysis we conclude that Icosapent Ethyl may have been a determining factor in Long COVID symptom resolution and should be studied further. | ||
| 700 | 1 | |a Callahan, Joseph Xavier |4 aut | |
| 700 | 1 | |a Raso, Isabella |4 aut | |
| 700 | 1 | |a Valencia, Bryceida |4 aut | |
| 700 | 1 | |a Eskander, Jonathan |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of complementary and integrative medicine |d De Gruyter, 2004 |g 20(2023), 3 vom: 07. Juni, Seite 662-664 |h Online-Ressource |w (DE-627)GRUY000014656 |w (DE-600)2197618-1 |w (DE-576)266225748 |x 1553-3840 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:3 |g day:07 |g month:06 |g pages:662-664 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1515/jcim-2023-0129 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.98 |j Alternativmedizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 3 |b 07 |c 06 |h 662-664 | ||